| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/09/2007 | US7160884 1-/2-substituted-1H/-2H-[1,2,3]triazolo[4,5-g]phthalazine-4,9-dione compound, process for the preparation thereof and pharmaceutical composition comprising the same |
| 01/09/2007 | US7160883 Pyrrolo-triazine aniline compounds useful as kinase inhibitors |
| 01/09/2007 | US7160882 Long acting β-2-agonists and their use as medicaments |
| 01/09/2007 | US7160881 Crystalline modifications of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1 λ6-thiomorpholin-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide |
| 01/09/2007 | US7160880 Producing sedation, hypnosis, inducing anxiolysis, muscle relaxation; treating convulsions; CNS depressants; pharmacodynamic |
| 01/09/2007 | US7160879 Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1H-benzoimidazole analogues |
| 01/09/2007 | US7160878 Substituted heterocyclic amides |
| 01/09/2007 | US7160877 Aliphatic nitrogen-containing 5-membered ring compound |
| 01/09/2007 | US7160876 Fused bicycloheterocycle substituted quinuclidine derivatives |
| 01/09/2007 | US7160875 Malonamide derivatives |
| 01/09/2007 | US7160874 Phenylalanine derivatives |
| 01/09/2007 | US7160873 Texaphyrin coordination compounds and uses thereof |
| 01/09/2007 | US7160872 Methods to treat conditions mediated by chemokine receptors |
| 01/09/2007 | US7160871 Nitrate esters of corticoid compounds and pharmaceutical applications thereof |
| 01/09/2007 | US7160870 Thrombopoietin mimetics |
| 01/09/2007 | US7160868 Nr-CAM gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors |
| 01/09/2007 | US7160867 Rapamycin carbohydrate derivatives |
| 01/09/2007 | US7160866 Isolation of tigogenin pentaglycoside from Chlorophytum nimonii |
| 01/09/2007 | US7160865 Heterocyclic alcohols such as 2-deoxy-D-glucose or 5-thio-D-glucose, used as anticarcinogenic agents or angiogenesis inhibitors; glycolysis antagonists |
| 01/09/2007 | US7160857 Methods for increasing schwann cell survival |
| 01/09/2007 | US7160855 Enhancement of iron chelation therapy |
| 01/09/2007 | US7160723 Composition for use in isolation of blood cell |
| 01/09/2007 | US7160692 Detecting DNA damage by identifying the activation state of Ataxia Telangiectasia-Mutated kinase by determining the phosphorylation state of a specific serine residue |
| 01/09/2007 | US7160684 Methods of selecting compounds for modulation of bladder function |
| 01/09/2007 | US7160580 Mixing protein (soy) or hydrocolloid (carboxyl methylcellulose) in water, adding glycerol, heating the mixture create a film solution and adding an organic acid (malic acid) |
| 01/09/2007 | US7160560 Skin-care composition |
| 01/09/2007 | US7160559 Galantamine hydrobromide particles and a water soluble film forming polymer are layered or coated on inert spheres, covered by a release rate controlling membrane made of a water insoluble polymer and optionally a plasticizer; galantamine and water-soluble polymer topcoat |
| 01/09/2007 | US7160556 Immediate release medicinal compositions for oral use |
| 01/09/2007 | US7160555 Antidiabetic agents |
| 01/09/2007 | US7160539 Altering T cell mediated immunity comprising altering local extracellular concentrations of tryptophan and tryptophan metabolites |
| 01/09/2007 | US7160538 Employing 1,1,1,2,3,3,3-heptafluoropropane as the sole propellant gas for administration of micronized or powdered drugs by inhalation |
| 01/09/2007 | CA2467490C Pharmaceutical compositions of 5,8,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene |
| 01/09/2007 | CA2407538C Novel bicyclic compounds |
| 01/09/2007 | CA2400801C Treatment of congestive heart failure by pretreated autologous blood |
| 01/09/2007 | CA2389325C 1-amino-alkylcyclohexane nmda receptor antagonists |
| 01/09/2007 | CA2375372C Mutual prodrugs of amlodipine and atorvastatin |
| 01/09/2007 | CA2372646C Method for manufacturing rumen bypass feed supplement |
| 01/09/2007 | CA2344407C Method for the treatment of mania and bipolar disorder |
| 01/09/2007 | CA2344248C 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors |
| 01/09/2007 | CA2343376C Sustained release ranolazine formulations |
| 01/09/2007 | CA2340056C Pharmaceutical compositions containing lipase inhibitors |
| 01/09/2007 | CA2338276C Fkbp inhibitors |
| 01/09/2007 | CA2333427C Foaming composition for hair care |
| 01/09/2007 | CA2315246C Topical compositions for enhancing glutathione production |
| 01/09/2007 | CA2308520C Strictly alternating poly(alkylene oxide ether) copolymers |
| 01/09/2007 | CA2301165C In situ formation of polymeric material |
| 01/09/2007 | CA2296731C Methods of preparing and purifying 9-nitro-20-camptothecin |
| 01/09/2007 | CA2294033C Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation |
| 01/09/2007 | CA2269134C A novel polymorphic crystalline form of fluticasone propionate, a method for its production and pharmaceutical compositions thereof |
| 01/09/2007 | CA2266444C Olanzapine dihydrate d |
| 01/09/2007 | CA2263129C Mammalian cell surface antigens; related reagents |
| 01/09/2007 | CA2260790C Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors |
| 01/09/2007 | CA2260145C Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1 |
| 01/09/2007 | CA2251702C Biologically active composition |
| 01/09/2007 | CA2251564C Buccal, non-polar spray for nitroglycerin |
| 01/09/2007 | CA2240721C Implantable acrylamide copolymer hydrogel for therapeutic uses |
| 01/09/2007 | CA2237554C A method and apparatus for producing liposomal parenteral medicaments via high pressure homogenization |
| 01/09/2007 | CA2232325C Tumor rejection antigens presented by hla-b44 molecules, and uses thereof |
| 01/09/2007 | CA2227533C Improved therapeutic agents |
| 01/09/2007 | CA2223011C Oxazolidinone derivatives, their preparation and therapeutical use |
| 01/09/2007 | CA2217836C Improved process for producing valproic acid |
| 01/09/2007 | CA2210985C Pharmaceutical composition containing fenofibrate and polyglycolized glycerides |
| 01/09/2007 | CA2203885C Treating red blood cell solutions with anti-viral agents |
| 01/09/2007 | CA2196271C Quinolone- or naphthyridonecarboxylic acid derivative or salt thereof |
| 01/09/2007 | CA2186844C Use of serotonin antagonists (5ht3) for treating fibromyalgia |
| 01/09/2007 | CA2180296C Treatment of arteriosclerosis and xanthoma |
| 01/09/2007 | CA2176511C Biologically active silicon compounds and their therapeutic and cosmetic applications |
| 01/09/2007 | CA2169831C Cosmetic melanins |
| 01/09/2007 | CA2165836C Use of rosmanol derivatives for producing antiradical and/or antilipoperoxidative and/or hepatotropic drugs |
| 01/09/2007 | CA2159988C Novel deoxygalactonojirimycin derivatives |
| 01/09/2007 | CA2144293C Substituted propane derivatives, a process for their preparation and the use of the compounds for treating diseases |
| 01/09/2007 | CA2142700C 3-oxo-pyrido(1,2-a)benzimidazole-4-carboxyl and 4-oxo-azepino(1,2-a)benzimidazole-5-carboxyl derivatives useful in treating central nervous system disorders |
| 01/09/2007 | CA2142126C Inhalation powder containing antistatic agent |
| 01/09/2007 | CA2102780C Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
| 01/09/2007 | CA2095153C Genetic modification of endothelial cells |
| 01/09/2007 | CA2077637C Compositions comprising a tramadol material and any of codeine, oxycodone or hydrocodone and their use |
| 01/08/2007 | WO2007007686A1 Composition for prevention of occurrence of cardiovascular event |
| 01/07/2007 | CA2551622A1 Dietary supplement for enhancing skeletal muscle mass, decreasing muscleprotein degradation, downregulation of muscle catabolism pathways, and decreasing catabolism of muscle cells |
| 01/04/2007 | WO2007002945A2 P2y6 receptor agonists for treating lung diseases |
| 01/04/2007 | WO2007002931A2 Phosphoramidate alkylator prodrugs |
| 01/04/2007 | WO2007002928A2 Treatment of occlusive thrombosis |
| 01/04/2007 | WO2007002912A2 Anti-proliferative compounds, compositions, and methods of use thereof |
| 01/04/2007 | WO2007002910A1 Quadraphasic continuous graduated estrogen contraceptive |
| 01/04/2007 | WO2007002906A1 Methods and dosage forms for reducing side effects of carbamate compounds |
| 01/04/2007 | WO2007002897A2 Compositions to improve the bioavailability of polymethoxyflavones and tocotrienols for treatment of cardiovascular disease |
| 01/04/2007 | WO2007002885A2 Compositions and methods for use of a sodium channel blocker |
| 01/04/2007 | WO2007002884A2 4-fluoro-piperidine t-type calcium channel antagonists |
| 01/04/2007 | WO2007002881A2 Compositions and methods of use of derivatized flavanols |
| 01/04/2007 | WO2007002867A1 Abca1 elevating compounds |
| 01/04/2007 | WO2007002862A2 Compositions and methods for treatment of cycle-related symptoms |
| 01/04/2007 | WO2007002851A2 Thermally-processed cocoa products useful for vascular health improvement |
| 01/04/2007 | WO2007002842A2 Substituted n-cinnamyl benzamides |
| 01/04/2007 | WO2007002831A2 Topical skin treating compostions |
| 01/04/2007 | WO2007002823A2 Formulations of conjugated estrogens and bazedoxifene |
| 01/04/2007 | WO2007002808A1 Anti-nonmelanoma carcinoma compounds, compositions, and methods of use thereof |
| 01/04/2007 | WO2007002764A2 Di-substituted oxadiazoles as cxc-chemokine receptor ligands |
| 01/04/2007 | WO2007002742A1 Substituted [1,4]-diazepanes as cxcr3 antagonists and their use in the treatment of inflammatory disorders |
| 01/04/2007 | WO2007002739A2 Chromium-amino acid complexes in the treatment of diabetes and other diseases |
| 01/04/2007 | WO2007002670A2 Method of lowering intraocular pressure |
| 01/04/2007 | WO2007002667A2 Azaindazole compounds and methods of use |